Format

Send to

Choose Destination
Joint Bone Spine. 2019 Sep 9. pii: S1297-319X(19)30119-8. doi: 10.1016/j.jbspin.2019.08.001. [Epub ahead of print]

Exposure to TNF Antagonist Therapies Induces Variations of the Gut Microbiota in an in vivo Model Using Healthy Mice.

Author information

1
U. S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA. Electronic address: Odile.Engel@fda.hhs.gov.
2
U. S. Food and Drug Administration, Center for Drug Evaluation and Research, Division of Biotechnology Review and Research 1, Silver Spring, MD, USA.
3
U. S. Food and Drug Administration, Center for Biologicals Evaluation and Research, Facility for Biotechnology Resources, Silver Spring, MD, USA.
4
U. S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of New Drugs, Office of Hematology and Oncology Products, Silver Spring, MD, USA.
5
U. S. Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Biostatistics and Epidemiology, HIVE, Silver Spring, MD, USA.

KEYWORDS:

Gut microbiome; TNF inhibitors; dysbiosis

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center